About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Cardiovascular Diseases group is a translational research group within the Cardiology Department of Vall d’Hebron Hospital that performs laboratory, clinical and epidemiological research. In the CIBERCV network we are within the topic of descriptor 2 “Arterial disease, thrombosis and myocardial ischemia-reperfusion injury”. Our contributions in these topics address the following lines:
In the CIBERESP network, our group is interested in the study of effectiveness/cost-effectiveness of cardiovascular interventions, health outcome research and methods in clinical research. The group has 19 principal investigators, 32 active projects and clinical trial and has been done 142 publications in 2020.
IP: José Raul Herance Camacho Collaborators: Beatriz Minguez Rosique, Clara Ramírez Serra, Cristina Gamez Cenzano, Juan Manuel Pericas Pulido, Nuria Roson Gradaille, Andreea Ciudin Mihai, Elena Maria Diaz Medina, Carolina Aparicio Gomez, Alberto Roque Pérez, Eduard Mas Carrió, Ramón Vilallonga Puy, Maria Nazarena Pizzi, Enrique Franky Vargas, Khadija Hassan Hammawa Funding agency: EUROPEAN COMMISSION Funding: 724000 Reference: ARTEMIS_HE-HLTH2023 Duration: 01/01/2024 - 31/12/2027
IP: Javier Inserte Igual Collaborators: Ignacio Ferreira González, José Antonio Barrabés Riu, Angeles Rojas Lopez, Antonio Rodríguez Sinovas, David Aluja Gonzalez, Sara Delgado Tomás, Andrea Guala Funding agency: Fundació La Marató de TV3 Funding: 150000 Reference: 202321-31 Duration: 11/03/2024 - 10/03/2027
IP: Begoña Benito Villabriga Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, Belen Perez Dueñas, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido i Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Maria Jose Pérez García, Miguel Segura Ginard, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Cristina Auger Acosta, Neus Bellera Gotarda, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno Garcia del Blanco, Ana Vivancos Prellezo, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Sandra Mancilla Zamora, Ana Zabalza de Torres, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Gabriela Guillén Burrieza, David Gómez Andrés, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Jaume Capdevila Castillon, Nicolás Miguel Fissolo , Maria Nazarena Pizzi, Paolo Giovanni Nuciforo, Tian Tian, Andrea Guala , Juan Pablo Betancur Rengifo Funding agency: Instituto de Salud Carlos III Funding: 2494527.53 Reference: FORT23/00034 Duration: 01/01/2024 - 31/12/2027
IP: José Antonio Barrabés Riu Collaborators: Ignacio Ferreira González, David Beneitez Pastor, David Aluja Gonzalez, Sara Delgado Tomás, Laura Castellote Bellés, Javier Inserte Igual Funding agency: Sociedad Española de Cardiologia Funding: 15000 Reference: SEC/FEC-INV-BAS 23/11 Duration: 01/01/2024 - 31/12/2027
Women have a mortality rate of 21% during the 30 days following surgery, compared with 11% in men, a difference that remains after taking patients’ clinical characteristics into account.
The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.
The study, with the participation of VHIR, will analyse the physiological response of the human body thanks to data collected by smartwatches and wearable devices.
Echocardiography Rates
PDF 0.66 MB
Hemodynamics Rates
PDF 0.47 MB
